How India Exports Cabazitaxel to the World

In the United States, cabazitaxel is approved for the treatment of metastatic castration-resistant prostate cancer. The FDA's Orange Book lists several approved Abbreviated New Drug Applications (ANDAs) for cabazitaxel injection. Notably, on July 20, 2018, Breckenridge Pharmaceutical, Inc. received tentative approval for their ANDA 207619, with final approval granted on October 27, 2022. This approval indicates that the generic formulation is bioequivalent and therapeutically equivalent to the reference listed drug, Jevtana Injection, 60 mg/1.5 mL (40 mg/mL), by Sanofi-Aventis U.S. LLC. The presence of multiple ANDA approvals reflects a competitive market landscape, offering opportunities for Indian exporters to supply active pharmaceutical ingredients (APIs) or finished formulations to U.S. manufacturers.

In the European Union, cabazitaxel is marketed under the brand name Jevtana, which received marketing authorization on March 17, 2011. Generic versions have also been approved; for instance, Cabazitaxel Accord was authorized on August 28, 2020. However, not all applications have been successful. On April 26, 2019, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for Cabazitaxel Teva, recommending refusal of its marketing authorization. This decision underscores the stringent regulatory requirements in the EU, emphasizing the need for comprehensive clinical data and adherence to Good Manufacturing Practice (GMP) standards. For Indian exporters targeting the EU and UK markets, compliance with these regulations is imperative to ensure successful market entry.

Cabazitaxel is not currently listed on the WHO Model List of Essential Medicines. Consequently, it has not undergone the WHO Prequalification Programme, which primarily focuses on medicines for high-burden diseases. Nonetheless, cabazitaxel formulations must comply with international pharmacopoeial standards, including those set forth in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures product quality and facilitates acceptance in global markets.

In India, cabazitaxel is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. As of March 2026, cabazitaxel is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), meaning it does not have a government-mandated ceiling price. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

Cabazitaxel's primary patents have expired, leading to increased generic competition. For example, U.S. Patent Number 7,241,907 expired on June 10, 2026, and U.S. Patent Number 8,927,592 is set to expire on April 27, 2031. The expiration of these patents has opened the market to generic formulations, intensifying competition among manufacturers and potentially impacting pricing strategies.

In October 2022, the FDA approved Breckenridge Pharmaceutical's generic cabazitaxel injection, enhancing market competition and potentially reducing treatment costs. In April 2023, the EMA updated the product information for Jevtana to include new safety data, emphasizing the importance of ongoing pharmacovigilance. In June 2023, the EMA's CHMP adopted a positive opinion for Cabometyx, recommending a new indication for neuroendocrine tumors, reflecting the dynamic nature of oncology drug approvals. In September 2023, the WHO updated its Model List of Essential Medicines, though cabazitaxel was not included, indicating ongoing evaluations of treatment priorities. In December 2023, the NPPA in India reviewed the pricing of various oncology drugs, though cabazitaxel remained outside the purview of price control, highlighting the agency's selective approach to drug pricing regulations.

These developments underscore the evolving regulatory and market landscape for cabazitaxel, necessitating continuous monitoring by stakeholders to navigate the complexities of global pharmaceutical trade.

Cabazitaxel, a semi-synthetic taxane derivative used in prostate cancer treatment, relies on complex synthesis processes involving Key Starting Materials (KSMs). India, a major producer of Active Pharmaceutical Ingredients (APIs), imports a significant portion of these KSMs from China. This dependency is particularly pronounced in the production of taxane-based APIs like cabazitaxel, where China's dominance in KSM supply creates a strategic chokepoint. According to a 2024 report by the U.S. Pharmacopeia, many APIs depend on sole-sourced KSMs from China, highlighting the vulnerability in the supply chain.

Recent disruptions have underscored this risk. For instance, in November 2024, India inaugurated two greenfield plants under the Production Linked Incentive (PLI) scheme to manufacture critical molecules like Penicillin G and 6-APA, aiming to reduce import dependence. However, these efforts primarily target antibiotics, leaving other sectors, including oncology drugs like cabazitaxel, still vulnerable to supply chain disruptions stemming from China's control over KSMs.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of cabazitaxel account for 69.7% of total exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 38.4%. This high supplier concentration poses a significant single-source risk. While the PLI scheme has incentivized domestic production of certain APIs and KSMs, its focus has been more on antibiotics and less on complex oncology drugs like cabazitaxel. Consequently, the cabazitaxel supply chain remains susceptible to disruptions due to limited diversification among suppliers.

Geopolitical tensions and shipping disruptions further exacerbate supply chain vulnerabilities. The Strait of Hormuz, a critical chokepoint for global oil shipments, has experienced heightened tensions as of March 2026. A prolonged closure could lead to inflation spikes and trade disruptions, impacting industrial outputs in major manufacturing economies like India and China. Additionally, the Red Sea and the Strait of Hormuz are vital routes for shipping raw materials and finished pharmaceutical products. Any instability in these regions can disrupt the timely delivery of essential components, affecting the production and export of cabazitaxel.

• Diversify KSM Sources: Encourage the development of alternative KSM suppliers outside of China to reduce dependency and mitigate risks associated with supply disruptions.

• Expand Domestic Production: Leverage the PLI scheme to include incentives for the domestic production of KSMs and APIs specific to oncology drugs like cabazitaxel.

• Strengthen Supplier Networks: Broaden the supplier base for cabazitaxel exports to reduce single-source dependency and enhance supply chain resilience.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events affecting key shipping routes and develop contingency plans to address potential disruptions.

• Enhance Inventory Management: Maintain strategic stockpiles of critical KSMs and APIs to buffer against short-term supply chain interruptions.

RISK_LEVEL: HIGH